Remove Bioinformatics Remove Research Remove RNA
article thumbnail

NGS is evolving: collaboration and tech lead the way

Drug Target Review

Research by Markets and Markets projects the market to grow from $12.13 1 Emergen Research attributes this to the advantages of high-throughput sequencing technologies and declining sequencing costs​. 2 This trend reflects the increasing demand for genomic sequencing in research, clinical diagnostics and other applications.

RNA 92
article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 1

Drug Target Review

In drug discovery and biological research, the scientists workflow often follows a structured and iterative approach to ensure accuracy, reproducibility and scientific integrity. At the heart of any research is the scientific question. This acts as a safeguard against false positives and misinterpretation of the data.

RNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What single cells are revealing about brain disorders

Drug Target Review

At the centre of this shift is 10x Genomics – a company building tools that enable researchers to study individual cells and their gene activity, both in isolation and in their original spatial context. I got my eyes opened to molecular biology, bioinformatics, computational biology and these emerging fields at the time.”

article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

This second ELRIG meeting on Therapeutic Oligonucleotides brings together esteemed scientists from academia, industry, and other members of the drug discovery community to explore the discovery, validation, and targeting of oligonucleotide-based drug candidates, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA).

RNA 59
article thumbnail

Case study: gget’s new Open Target module

The Open Targets Blog

  “Sam has an exceptional talent in software engineering, and his contributions reflect a deep understanding of both the technical and biological aspects required for bioinformatics tool development,” says Laura Luebbert, now a postdoctoral fellow in the Sabeti lab at the Broad Institute of MIT and Harvard and Harvard University.

article thumbnail

Fixing failed drugs: AI solutions for toxicity in drug discovery – part 2

Drug Target Review

In Part 2 of our conversation with Layla Hosseini-Gerami, Chief Data Science Officer at Ignota Labs , we explore the many forms of toxicity and how AI-powered tools like omics and cell painting are transforming early prediction in pre-clinical research. How can we understand what the consequences of that are?”

Drugs 73
article thumbnail

What Makes a Mature Science

Codon

There's a sharp divide between "impressionistic" research that deals with simple predictions and abstract nouns (merely documenting effects and phenomena) and “mechanical research” that attempts to model what we observe in terms of rules and entities. We need to help the Spinozas of bioinformatics grind out new lenses.

Science 79